Why 30 mg Twice Daily Fails: Anti-Factor Xa Monitoring and the Persistent Dosing Gap in High-Risk Trauma Patients
- 4 September 2026
- journal article
- research article
- Published by SAGE Publications in The American Surgeon™
Abstract
Introduction: Contemporary trauma guidelines support higher initial enoxaparin dosing for adult trauma patients, as standard dosing (30 mg twice daily [BID]) frequently fails to achieve target anticoagulant activity. While anti-factor Xa (anti-Xa) monitoring guides dose adjustments, real-world implementation of follow-up monitoring remains variable. This study evaluated anti-Xa target attainment, dose escalation practices, and completion of follow-up monitoring in high-risk trauma patients. Methods: This retrospective cohort study at a Level I trauma center included adult trauma patients (April 2022-October 2023) receiving enoxaparin venous thromboembolism prophylaxis who underwent at least one anti-Xa measurement. Demographics, Injury Severity Score (ISS), dosing changes, and repeat monitoring frequencies were analyzed. This study evaluated real-world clinical practice and was not designed to compare dosing strategies or assess a protocolized intervention. Results: Among 244 patients (median ISS 22; 43% with BMI >40 kg/m 2 ), 80% initially received standard dosing (30 mg BID). Only 42% achieved target prophylactic anti-Xa levels (0.2–<0.5 IU/mL). Of those on standard dosing, 34% required escalation, with the mean adjusted dose approaching 40 mg BID. While 68% of patients who underwent repeat testing after dose escalation successfully achieved target levels, repeat monitoring was completed in only 22% of all adjusted patients. Venous thromboembolism occurred in 5%, and bleeding in 7%. Conclusion: Standard enoxaparin dosing frequently fails high-risk trauma patients, supporting contemporary higher-dose guidelines. However, a critical implementation gap persists; while clinicians recognize subtherapeutic levels and escalate doses, follow-up anti-Xa monitoring is inconsistently performed. Standardized tracking protocols and automated electronic triggers are required to close the loop in anti-Xa pathways.Keywords
This publication has 29 references indexed in Scilit:
- Increased Prophylactic Enoxaparin Dosing Is Associated With Improved Achievement of Target anti-Xa Levels; Implementation of the Western Trauma Association Venous-Thromboembolism GuidelinesJournal of Surgical Research, 2026
- Multicenter study evaluating target attainment of anti‐Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patientsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024
- Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative ReviewAdvances in Therapy, 2022
- Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysisJournal of Trauma and Acute Care Surgery, 2022
- Antithrombotic Therapy for VTE DiseaseChest, 2021
- A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma PatientsJournal of Surgical Research, 2021
- Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithmJournal of Trauma and Acute Care Surgery, 2020
- Venous thromboembolism (VTE) prophylaxis in severely injured patients: an international comparative assessmentEuropean Journal of Trauma and Emergency Surgery, 2019
- Pharmacokinetics and Pharmacodynamics of Enoxaparin in Multiple Trauma Patients2005
- Practice Management Guidelines for the Prevention of Venous Thromboembolism in Trauma Patients: The EAST Practice Management Guidelines Work Group2002